SecBot SecBot
SECBOTREPLAY Home › Report › EBS

EBS · Emergent BioSolutions announced a ~$34.5M agreement with Substipharm…

Emergent BioSolutions · PRESS-RELEASE filed Apr 28, 2026 at 08:01 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Apr 28, 2026 at 08:01 ET

Emergent BioSolutions announced a ~$34.5M agreement with Substipharm Biologics to manufacture drug substance for the IMOJEV Japanese Encephalitis vaccine at its Canton, MA facility and to serve as exclusive U.S. government distributor upon FDA approval. The deal leverages Emergent's recently cleared Canton facility (FDA 'No Action Indicated' status) and provides a new revenue stream, but the vaccine is not yet FDA-approved and the total value is modest relative to EBS's $415M market cap.

  • Agreement valued at approximately $34.5 million.
  • Emergent will manufacture IMOJEV drug substance at its Canton, MA facility.
  • Emergent will be exclusive distributor of IMOJEV to the U.S. government upon FDA approval.
  • Canton facility received FDA 'No Action Indicated' status after February 2026 inspection.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access